Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Trial of Hypofractionation Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS Metastatic Colorectal Carcinoma (mCRC)

NCT05292417 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Xiamen University as lead sponsor.

NCT NCT05292417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05292417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Trial of Hypofractionation Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS Metastatic Colorectal Carcinoma (mCRC)
Lead sponsor
The First Affiliated Hospital of Xiamen University
Phase
Phase 2
Overall status
Unknown status
Start date
March 25, 2022
Completion date
March 31, 2024
Enrollment
71 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms